Article
Oncology
Ryosuke Ono, Kosuke Takayama, Fuminori Sakurai, Hiroyuki Mizuguchi
Summary: The study developed a novel OAd fully composed of OAd35, which recognizes CD46 as an infection receptor and showed efficient cell lysis activities similar to OAd5 in CAR-positive tumor cells, while exhibiting higher levels of cell lysis activities than OAd5 in CAR-negative tumor cells. OAd35 had lower proportions of neutralizing antibodies in adults compared to Ad5.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
Fang Dai, Peng-Bo Zhang, Qiang Feng, Xin-Yan Pan, Shu-Ling Song, Jing Cui, Ju-Lun Yang
Summary: A novel strategy combining oncolytic adenovirus with CIK cells for treating Ras-driven liver cancer was developed. The in vivo study showed significantly inhibited tumor growth with little effect on normal organs, indicating relative safety.
Article
Oncology
Hailin Zhang, Yonghui Zhang, Jie Dong, Binghua Li, Chun Xu, Min Wei, Junhua Wu, Jiwu Wei
Summary: The study showed that Ad5sPVR treatment increased the infiltration of CD8(+) T cells and the release of interferon (IFN)-gamma, exhibiting an antitumor effect with long-term tumor-specific immune surveillance. Furthermore, Ad5sPVR also effectively improved antitumor outcomes in solid tumors.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
Giulia Raimondi, Sabrina Gea-Sorli, Marc Otero-Mateo, Cristina Fillat
Summary: Oncolytic adenoviruses are replication-competent viruses designed for cancer treatment, with miR-222 playing a crucial role as a limiting factor. Through genetic engineering of adenovirus with miR-222 sponges, the viral activity has been significantly improved.
Article
Microbiology
Xiaohui Han, Jingshuai Sun, Xiaocheng Lv, Xiaoyu Tang, Yubin Zheng, Jinyun Ma, Yuan Sun
Summary: In this study, a recombinant pseudorabies virus (PRV) carrying exogenous IL-18, IFN-?, and PH20 genes was constructed and evaluated for its tumorolytic effects. The results showed that the recombinant PRV effectively lysed tumor cells and inhibited tumor growth in mice. Immunohistochemical analysis demonstrated enhanced anti-tumor immune response in vivo. This study provides a foundation for further development and application of PRV as a novel tumor oncolytic virus vector.
Review
Oncology
Marti Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino, Ramon Alemany
Summary: Cancer immunotherapy utilizing immune checkpoint inhibitors has shown effectiveness in various human cancers, but cold tumors often lack immune cells and are typically unresponsive. Oncolytic viruses, with their lytic and immunogenic mechanisms, have attracted interest as potential therapeutic approaches to heat or promote lymphocyte infiltration of cold tumors. This article reviews the use of oncolytic adenoviruses in cancer immunotherapy, focusing on immune responses triggered by these viruses against tumor antigens in preclinical and clinical settings, as well as considerations for clinical trial design and combination therapies with conventional treatments or other immunotherapies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Rui Ma, Ting Lu, Zhenlong Li, Kun-Yu Teng, Anthony G. Mansour, Melissa Yu, Lei Tian, Bo Xu, Shoubao Ma, Jianying Zhang, Tasha Barr, Yong Peng, Michael A. Caligiuri, Jianhua Yu
Summary: The study demonstrated that the combination therapy of an oncolytic virus expressing the IL15/IL15Rα complex and off-the-shelf EGFR-CAR NK cells elicited strong antitumor responses in glioblastoma. This therapy significantly inhibited tumor growth and improved survival rates, offering a promising strategy for the clinical management of this devastating disease.
Article
Oncology
Shuhei Shinoda, Nikita S. S. Sharma, Naohiko Nakamura, Kazuho Inoko, Mizuho Sato-Dahlman, Paari Murugan, Julia Davydova, Masato Yamamoto
Summary: Combining oncolytic adenovirus-expressing interferon (IFN-OAd) with chemotherapy and radiation can improve the survival rate and suppress tumor growth in pancreatic ductal adenocarcinoma (PDAC) patients without severe side effects. This treatment also induces a higher number of tumor-infiltrating lymphocytes. It is an effective and clinically beneficial therapy for PDAC patients.
Article
Immunology
Mohammad Shahnaij, Mitsuhiro Iyori, Hiroaki Mizukami, Mayu Kajino, Iroha Yamagoshi, Intan Syafira, Yenni Yusuf, Ken Fujiwara, Daisuke S. Yamamoto, Hirotomo Kato, Nobuhiko Ohno, Shigeto Yoshida
Summary: By using AAV8 as a booster, the immune responses in mice were improved, providing better protection against malaria and demonstrating great promise as a next-generation platform for effective malaria vaccine development.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Shaofeng Yuan, Xiangdong Kong, Wei Yu, Jinhong Geng, Linwen Zeng, Shengchun Dang
Summary: Colon cancer is a leading cause of tumor lethality worldwide, and the development of multidrug resistance poses challenges for effective control. The upregulation of circRNA_100920 in CRC tissues and cells suggests its potential as a biomarker for diagnosis, treatment, and prognosis of CRC. Further research on circRNA_100920 may lead to new therapeutic strategies for CRC.
Article
Oncology
Bin Zhang, Yongheng Shu, Shichuan Hu, Zhongbing Qi, Yanwei Chen, Jinhu Ma, Yunmeng Wang, Ping Cheng
Summary: In situ tumor vaccine utilizing oncolytic viruses and CD47-targeting nanobodies shows promise in inducing potent antitumor immune responses and remodeling the tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Erkko Ylosmaki, Leena Ylosmaki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jager, Sari Pesonen, Vincenzo Cerullo
Summary: Oncolytic virus therapies can enhance anti-cancer immunity by arming viruses with immunostimulatory molecules. The novel adenovirus VALOD-102 encoding CD40L and OX40L activates both innate and adaptive immune responses against tumors. In preclinical models, combination therapy with PeptiCRAd and anti-PD-1 immune checkpoint inhibitors shows promising results in controlling tumor growth.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Virology
Qing Zhang, Junwen Zhang, Yifu Tian, Jialin Wang, Guishan Jin, Fusheng Liu
Summary: In this study, the targeted oncolytic virus Ad5-Ki67/IL-15 was found to effectively down-regulate PD-L1 expression, remodel the tumor microenvironment, and increase the efficacy of GBM treatment. The combination of Ad5-Ki67/IL-15 with PD-L1 blockade further inhibits tumor growth.
Article
Medicine, Research & Experimental
Sharmila Nair, Luciano Mazzoccoli, Arijita Jash, Jennifer Govero, Sachendra S. Bais, Tong Hu, Camila R. Fontes-Garfias, Chao Shan, Hideho Okada, Sujan Shresta, Jeremy N. Rich, Pei-Yong Shi, Michael S. Diamond, Milan G. Chheda
Summary: Zika virus targets GBM stem cells and prevents tumor growth by recruiting CD8(+) T cells and myeloid cells. While anti-PD-1 antibody alone moderately improves survival, combining it with ZIKV treatment significantly increases survival rate. Immune-sensitized ZIKV strain shows promise for safe and effective combination therapy with immunotherapies for GBM patients.
Article
Biotechnology & Applied Microbiology
Shao-Chia Lu, Michael J. Hansen, Jack R. Hemsath, Brian J. Parrett, Brady N. Zell, Michael A. Barry
Summary: In this study, the efficacy of CRAds with and without immunostimulatory payloads in a mouse melanoma model was tested. It was found that the combined injection of two CRAds can lead to better control of tumor growth and improved anticancer immune responses.
HUMAN GENE THERAPY
(2022)
Article
Dermatology
Yeo Reum Jeon, Hyo Min Ahn, Il Kyu Choi, Chae Ok Yun, Dong Kyun Rah, Dae Hyun Lew, Won Jai Lee
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2016)
Article
Biochemistry & Molecular Biology
B. Min, H. Park, S. Lee, Y. Li, J-M Choi, J. Y. Lee, J. Kim, Y. D. Choi, Y-G Kwon, H-W Lee, S-C Bae, C-O Yun, K. C. Chung
Article
Chemistry, Multidisciplinary
Dae-Hwan Park, Jaeyong Cho, Oh-Joon Kwon, Chae-Ok Yun, Jin-Ho Choy
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2016)
Article
Biochemistry & Molecular Biology
Shyam Kishor Sah, Kyung Ho Park, Chae-Ok Yun, Kyung-Sun Kang, Tae-Yoon Kim
ANTIOXIDANTS & REDOX SIGNALING
(2016)
Article
Engineering, Biomedical
Young Sook Lee, Joung-Woo Choi, Jung-Eun Oh, Chae-Ok Yun, Sung Wan Kim
Article
Oncology
Youjin Na, Sunil C. Kaul, Jihoon Ryu, Jung-Sun Lee, Hyo Min Ahn, Zeenia Kaul, Rajkumar S. Kalra, Ling Li, Nashi Widodo, Chae-Ok Yun, Renu Wadhwa
Article
Cell Biology
Renu Wadhwa, Didik Priyandoko, Ran Gao, Nashi Widodo, Nupur Nigam, Ling Li, Hyo Min Ahn, Chae-Ok Yun, Nobuhiro Ando, Christian Mahe, Sunil C. Kaul
CELL STRESS & CHAPERONES
(2016)
Review
Pharmacology & Pharmacy
A-Rum Yoon, Jinwoo Hong, Sung Wan Kim, Chae-Ok Yun
EXPERT OPINION ON DRUG DELIVERY
(2016)
Article
Nanoscience & Nanotechnology
Goeun Choi, Huiyan Piao, Zeid A. Alothman, Ajayan Vinu, Chae-Ok Yun, Jin-Ho Choy
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2016)
Article
Chemistry, Multidisciplinary
A-Rum Yoon, Dayananda Kasala, Yan Li, Jinwoo Hong, Wonsig Lee, Soo-Jung Jung, Chae-Ok Yun
JOURNAL OF CONTROLLED RELEASE
(2016)
Article
Oncology
Adel Galal El-Shemi, Ahmad Mohammed Ashshi, Youjin Na, Yan Li, Mohammed Basalamah, Faisal Ahmad Al-Allaf, Eonju Oh, Bo-Kyeong Jung, Chae-Ok Yun
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2016)
Correction
Oncology
Adel Galal El-Shemi, Ahmad Mohammed Ashshi, Youjin Na, Yan Li, Mohammed Basalamah, Faisal Ahmad Al-Allaf, Eonju Oh, Bo-Kyeong Jung, Chae-Ok Yun
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2016)
Article
Biotechnology & Applied Microbiology
Ja Kyung Kim, Jung Il Lee, Yong-Han Paik, Chae-Ok Yun, Hye Young Chang, Su Yeon Lee, Kwan Sik Lee
JOURNAL OF GENE MEDICINE
(2016)
Review
Biotechnology & Applied Microbiology
Dayananda Kasala, A-Rum Yoon, Jinwoo Hong, Sung Wan Kim, Chae-Ok Yun
Article
Cell & Tissue Engineering
Yoon Ok Jang, Mee-Yon Cho, Chae-Ok Yun, Soon Koo Baik, Kyu-Sang Park, Seung-Kuy Cha, Sei Jin Chang, Moon Young Kim, Yoo Li Lim, Sang Ok Kwon
STEM CELLS TRANSLATIONAL MEDICINE
(2016)